Table 3.
Baseline demographics and clinical outcomes by smoking status and antiplatelet group.
| Currentsmokers (n = 1066)
|
p-Value | Never-smokers (n = 726)
|
p-Value | |||
|---|---|---|---|---|---|---|
| Clopidogrel (n = 383) | Aspirin (n = 683) | Clopidogrel (n = 240) | Aspirin (n = 486) | |||
| Demographics | ||||||
| Age (yr, mean ± SD) | 58.27 ± 11.65 | 59.40 ± 11.49 | 0.128 | 64.96 ± 12.73 | 61.71 ± 13.84 | 0.002 |
| Male (%) | 367 (95.8) | 650 (95.2) | 0.625 | 98 (40.8) | 220 (45.3) | 0.257 |
| Clinical History (n, %) | ||||||
| Hypertension | 248 (64.8) | 434 (63.5) | 0.693 | 181 (75.4) | 313 (64.4) | 0.003 |
| Diabetes | 123 (32.1) | 181 (26.5) | 0.051 | 83 (35.0) | 143(29.4) | 0.127 |
| Hyperlipidemia | 176 (46.0) | 293 (42.9) | 0.335 | 92(38.3) | 172 (35.4) | 0.438 |
| Prior coronary heart disease | 49 (12.8) | 83 (12.2) | 0.760 | 40 (16.7) | 64 (13.2) | 0.206 |
| Primary outcome (n, %) | ||||||
| Secondary ischemic stroke | 12 (3.1) | 34 (5.0) | 0.155 | 4 (1.7) | 5 (1.0) | 0.488 |
| Myocardial infarction | 2 (0.5) | 8 (1.2) | 0.292 | 1 (0.4) | 0 | 0.331 |
| All-cause death | 0 | 2 (0.3) | 0.289 | 0 | 0 | n/a |
| All primary events | 14 (3.7) | 44 (6.4) | 0.096 | 5 (2.1) | 5 (1.0) | 0.312 |
| Safety endpoint (n, %) | ||||||
| Bleeding events | 9 (2.3) | 12 (1.8) | 0.504 | 1 (0.4) | 2 (0.4) | 1.000 |